Use of Prophylactic Drugs according to Risk Classification for TLS in Patients with Hematological Malignancies

Abstract

Background : Tumor lysis syndrome (TLS) is a metabolic syndrome caused by the release of intracellular uric acid, potassium, and phosphorus into the blood due to sudden tumor necrosis. If inadequate prophylactic therapy for TLS or treatment is delayed, complication risks may increase. Therefore, it is important to identify patients at high risk of TLS before chemotherapy. In this study, appropriate prophylactic drug use for TLS risk groups was investigated, and its association with TLS occurrence was analyzed. Methods :From January 2019 to December 2021, electronic medical records of adult hematologic oncology patients aged ≥19 years who were hospitalized for their first chemotherapy for hematological tumors were retrospectively analyzed. Diagnosis, hematological -60 -